临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 152459-95-5

Imatinib (STI571)

中文名称:伊马替尼
CAS号:152459-95-5
分子式: C29H31N7O 分子量: 493.60
产品形式: free base
研发状态: Recruiting
研发用途: Gastrointestinal Stromal Tumors
研究机构: Reema A. Patel; University of Kentucky
研发日期: March 26 2024
研发阶段: Phase 2
Imatinib (STI571,Gleevec, Glivec, CGP057148B) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. Imatinib (STI571) induces autophagy.

CAS: 152-11-4

Verapamil (CP-16533-1) HCl

中文名称:盐酸维拉帕米
CAS号:152-11-4
分子式: C27H38N2O4.HCl 分子量: 491.06
产品形式: Hydrochloride
研发状态: Recruiting
研发用途: Angina Pectoris Variant; Angina Pectoris; Spasm-Induced; Angina Pectoris With Normal Coronary Arteriogram
研究机构: University Hospital Antwerp
研发日期: January 9 2023
研发阶段: Not Applicable
Verapamil HCl (CP-16533-1,(±)-Verapamil hydrochloride) is an L-type calcium channel blocker that is a class IV anti-arrhythmia agent. Verapamil inhibits both permeability-glycoprotein (P-gp) and CYP3A4.

CAS: 152044-54-7

Patupilone (Epothilone B)

中文名称: 埃博霉素B
CAS号:152044-54-7
分子式: C27H41NO6S 分子量: 507.68
产品形式: free base
研发状态: Completed
研发用途: Refractory Malignancy
研究机构: University of Medicine and Dentistry of New Jersey; Novartis Pharmaceuticals; National Cancer Institute (NCI); Rutgers The State University of New Jersey
研发日期: Jul-07
研发阶段: Phase 1
Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

CAS: 1513857-77-6

Pemigatinib (INCB054828)

中文名称:培米加替尼
CAS号:1513857-77-6
分子式: C24H27F2N5O4 分子量: 487.50
产品形式: free base
研发状态: Recruiting
研发用途: Advanced Solid Tumor; Unresectable Solid Tumor; Metastatic Solid Tumor; Cholangiocarcinoma
研究机构: Massachusetts General Hospital; Boehringer Ingelheim; Incyte Corporation
研发日期: July 1 2024
研发阶段: Phase 1
Pemigatinib (INCB054828, Pemazyre) is an orally active and selective inhibitor of FGFR with IC50 of 0.4 nM, 0.5 nM, 1.2 nM and 30 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.

CAS: 151096-09-2

Moxifloxacin

中文名称:莫西沙星
CAS号:151096-09-2
分子式: C21H24FN3O4 分子量: 401.43
产品形式: free base
研发状态: Recruiting
研发用途: Healthy
研究机构: Boehringer Ingelheim
研发日期: March 4 2024
研发阶段: Phase 1
Moxifloxacin is an antibiotic used to treat a number of bacterial infections, active against Mycobacterium tuberculosis in vitro.

CAS: 1508-75-4

Tropicamide

中文名称:托吡卡胺
CAS号:1508-75-4
分子式: C17H20N2O2 分子量: 284.35
产品形式: free base
研发状态: Recruiting
研发用途: Cadasil
研究机构: Perminder Sachdev; Prince of Wales Hospital Sydney; John Hunter Hospital; St Vincent''s Hospital - Sydney Australia; Royal Brisbane and Women''s Hospital; Melbourne Health; The University of Queensland; The University of New South Wales
研发日期: November 25 2023
研发阶段: --
Tropicamide(Ro 1-7683) is an anticholinergic and a muscarinic receptor subtype M4-preferring antagonist with IC50 of 8.0 nM.